Companies: 10,795·Total market cap: $144.5T
OmniAb, Inc.

OmniAb, Inc.

OABINASDAQHealthcare● Active
$2.28
$-0.20(-8.06%)
Market Cap$271526418
P/E Ratio
52W High$2.79
52W Low$1.3

OmniAb, Inc. (OABI) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

oabi · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for OmniAb, Inc. (OABI) measures how much investors pay for each dollar of the company's trailing earnings. OABI's current PE ratio of N/A is calculated by dividing its stock price of $2.28 by its TTM earnings per share of -$0.42.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.27
Based on 4 analysts
EPS (TTM)
-$0.42
TTM · diluted EPS
PEG Ratio
-0.26
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · OmniAb, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
OmniAb, Inc.
OmniAb, Inc.You
OABI
$272MN/A-$0.42
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.
ARMP
$278MN/A-$4.80
C4 Therapeutics, Inc.
C4 Therapeutics, Inc.
CCCC
$297MN/A-$1.27
Codexis, Inc.
Codexis, Inc.
CDXS
$237MN/A-$0.50
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.
IMDX
$154MN/A-$1.65
Innate Pharma S.A.
Innate Pharma S.A.
IPHA
$165MN/A-$0.55
Invivyd, Inc.
Invivyd, Inc.
IVVD
$135MN/A-$0.30

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.57
2024-12-31
FY2024
$-0.61
2023-12-31
FY2023
$-0.51
2022-12-31
FY2022
$-0.26
2021-12-31
FY2021
$-0.24
2020-12-31
FY2020
$-0.15
2019-12-31
FY2019
$-0.12

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for OmniAb, Inc. (OABI) measures how much investors pay for each dollar of the company's trailing earnings. OABI's current PE ratio of N/A is calculated by dividing its stock price of $2.28 by its TTM earnings per share of -$0.42.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.28 ÷ -$0.42 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

OABI pe ratio · 6 questions

OABI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.28 and TTM EPS of -$0.42. Data sourced from Financial Modeling Prep via OABI's SEC 10-K and 10-Q filings.

OABI PE ratioWhat is OABI PE ratioCurrent PE ratio of OABIOABI PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · OmniAb, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08